

Review Article

Clinical trials in nutrition

Mark L Wahlqvist¹ BMedSc, MD, BS (Adelaide), MD(Uppsala), FRACP, FAIFST, FACN, FAFPHM, Bridget H-H Hsu-Hage^{1,2} BSc, MS, PhD* and Widjaja Lukito³ MD, PhD

¹International Health & Development Unit, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia

²Department of Community Medicine and General Practice, Monash University, Melbourne, Victoria, Australia

³SEAMEO-TROPMED Regional Center for Community Nutrition, University of Indonesia, Jakarta, Indonesia.

Trials of nutritional intervention in a wide range of health and disease states, preventive and therapeutic, are required. Not only has the emergence of chronic non-communicable disease (CNCD) with acknowledged nutritional pathogenesis created this imperative need, but so also have other conditions which, previously, had not been regarded as nutritionally based. Among the latter are health problems associated with ageing: the menopause, a decline in immune function, and a decline in cognitive function. At the same time, there is a new set of materno-foetal and infant nutrition issues for investigation which relate to new food exposures and the long-term effects of nutritionally mediated gene expression. The emergence of the new food science of phytochemicals with human biological importance also sets the scene for their evaluation in traditional diets and novel foods. Such trials are more complex than comparable pharmacotherapeutic studies because of the complexity of food chemistry, as well as the food behavioural changes which may accompany a nutritional intervention, and the general problem of there not being a 'gold standard' for food intake methodology. Choice of study population is also a key issue in relation to the extrapolation of findings from a particular trial, with population representativeness being an advantage. In order to obtain useful information on manageable sample sizes, either intermediate end-points (short of morbidity and mortality) need to be studied or high-risk groups (such as the aged) need to be recruited. There are some unique ethical issues which must inform clinical nutrition trials. These include certain preventive imperatives like the right to be fed, the risks in disruption of food cultures and the need for food security and sustainability. Rapid changes in the food supply do, however, make such trials more important, while the value of food-health knowledge that cannot be obtained by trial must still be appreciated.

Key words: nutrition intervention, nutritional epidemiology, food trial, nutrition trial, compliance.

The rationale for nutritional clinical trials

Why trials in food and nutrition?

The observational and interventional stimulus of nutritional epidemiology. For most of human history, changes in the way we eat and the associated health changes have been slow, with efforts to improve health through food being made by trial and error.¹ The changes, for example, on migration or with major environmental change, may have been accepted or not appreciated. For example, the development of iodine deficiency disorders in a region may have been regarded as 'the way things are' or not attributed to food, although it is possible that importation of iodine-containing food items, with the resultant improvement of the problem, or migration to another area, with a decrease in prevalence, raised the possibility that a food factor might have been responsible.²

In more recent times, the formalization of such observations by way of nutritional epidemiology and clinical epidemiology has created opportunities for testing food and applying food factor solutions to the problems.³ Such evaluation may proceed by way of a community-based intervention; for example, by introducing iodized salt or a seaweed- or seafood-based product and measuring the change in prevalence. There have been numerous such trials, many of which have resulted in specific micronutrient deficiencies being considered major factors in the prevalence of disease.

These would include feeding programs for protein–energy malnutrition (PEM);⁴ iron supplementation or food fortification with iron for impaired cognitive function; or in microcytic hypochromic anaemia with increased iron intake; or a vitamin A supplementation or food fortification to prevent xerophthalmia.^{5–8}

Definition and acceptability of risk. Intervention trials, especially with micronutrients, have raised the prospect of demonstrating major benefits for a large fraction of the population and, although risk has generally been considered, it has not necessarily been defined and has been far outweighed by potential benefits. The lower the prevalence of the health problem, the less acceptable is the risk of a food or food vehicle intervention and the greater the need for risk definition.⁹ Thus, there has been considerable controversy about the introduction of food fortification with folate, which would affect consumption community-wide, in an effort to reduce the incidence of neural tube defects when a more targeted

Correspondence address: Prof. Mark L. Wahlqvist, International Health & Development Unit, Menzies Building, Monash University, Wellington Road, Clayton, Victoria 3168, Australia.
Tel: 61 3 9905 8145; Fax: 61 3 9905 8146
Email: mark.wahlqvist@med.monash.edu.au
Accepted 17 December 1998

approach using folate supplementation for women whose offspring are at risk might do just as well.^{10,11} Traditional food cultures and health problems may provide clues as to appropriate risk–benefit studies. For example, Chinese women traditionally use one of the best food sources of folate, namely chicken liver, throughout their reproductive years and then reduce their intake at a time when they are developing atrophic gastritis and a reduced capacity to absorb vitamin B-12, a deficiency in which may be exacerbated by folate.

Clinical trials which understand and characterize at-risk groups and offer them potential benefits through the use of particular foods or food components will be of increasing interest as the era of an inadequate food supply and related deficiency disorders recedes, and as the economic and educational status of populations improves. Such populations will be able to afford, and will want to be selective about, the food they choose in relation to their health.

The recognition of the relationships between food intakes and major non-communicable diseases (NCD) (e.g. cardiovascular, neoplastic and osteoporotic diseases, obesity, diabetes) initially stimulated the development of dietary guidelines for the public at large,¹² and now encourages a more selective approach based on a knowledge of genetic predisposition and of related lifestyle factors (e.g. physical activity, tobacco and alcohol consumptions, other substance abuse), and the health care system in which the individual operates.¹³ Again clinical trials will come to the fore in establishing the relationship between food intakes and NCD.

Consequences of major changes in food intake. The lessons so far for NCD are that in some health domains major improvements appear to have been made with regard to nutritional advice and change (e.g. reduce ischaemic heart disease through lowered saturated fat intake and possibly through increased polyunsaturated fat intake);¹⁴ however, the full health consequences of major changes in food intake tend not to be evaluated. For example, the change in fat quality towards ω -6 fatty acids and away from saturated fat, which began at the end of the 1960s, has scarcely been evaluated beyond hyperlipidaemia.¹⁵ Indeed, it is only now, 30 years or so later, that questions are being systematically asked about the safe upper limit of ω -6 fatty acid consumption.^{16,17} In future, it will be necessary to approach such novel changes to the human diet, such as those regarding fat amounts and quality, with clinical trials and with the appropriate toxicology (as best we know it at the time).

For other NCD, surprisingly little change has taken place in prevalence or incidence despite an apparently good appreciation of dietary linkages. Colorectal cancer (CRC) is an example, although^{18–21} the problem may in part be the competing effects of factors which increase and those which decrease risk. For example, if (saturated) fat increases the risk of CRC^{22,23} and whey proteins in milk decrease the risk,²⁴ reduced dairy product consumption may not benefit those at risk of this cancer. Or, without the present nutritional changes in fat, fruit, vegetable and cereal intake, the incidence of CRC may have been even higher. Randomized clinical trials over long time frames may be needed to resolve these issues. The problem will be the cost and management of such research exercises as these may be so prohibitive that other methods of enquiry may be required. Alternatively the

approach may not be ethically implementable for the outcome in question.²⁵

Development of criteria. Any clinical trial should satisfy at least three basic criteria before initiation: (i) plausibility of hypothesis; (ii) feasibility; and (iii) justifiable cost (of the study and of the envisaged nutritional intervention).

Quest for disease mechanism. Clinical trials in food and nutrition have considerable potential significance for the biomedical sciences as far as disease mechanisms are concerned. They will enable us to test and identify food properties and compounds, the alteration of which may facilitate the prevention and management of disease.

Food and health relationships

Presumptive causality and its evaluation. One of the major tasks for clinical nutrition trials is to establish causality among the many established food and health relationships which have emerged from cross-sectional community-based studies, and from observational, cohort and case-control studies.

There remain areas of human biology likely to be significantly affected by diet for which the prima facie case for food component dependency, through identification of relationships, have scarcely been advanced. These would include the following: menstrual function,²⁶ menopause,²⁷ immune function,²⁸ cognitive function,^{29–32} olfaction and memory.³³

Assignment of importance. If causality is established by way of controlled interventions and/or trials, the relative importance of nutritional factors, as opposed to others, needs consideration as does the dose–response relationship and the durability of, and tolerance to or adaptation to, the effects. One of the remarkable features of the human diet appears to be the range of options compatible with health, presumably due, in part, to the alternative ways of achieving the same biological outcome (e.g. antioxidation through the selenium metallo-enzyme glutathione peroxidase or through tocopherols).^{34,35}

Dealing with food chemical and dietary complexities. Because of dietary intricacies or complexities, it is important to consider whether clinical trials will miss the effects of a potential food factor or only see them in the context of other nutritional or non-nutritional problems (e.g. combined as opposed to single antioxidant deficiency, different levels of physical activity). It is an advantage to design trials so that several factors can be considered at once.^{13,27,36,37}

Some clinical trials in nutrition will have to mathematically model food intake as meals, day-long patterns or patterns over longer periods. We know little, for example, about meal time bioavailabilities or responses to some nutrients;³⁸ of diurnal variations of nutrient intakes or their effects (e.g. thiamin at breakfast from cereals, zinc at the evening meal from meat);³⁹ or of the day-to-day fluctuations in nutrient intakes where the nutrient in question is stored for shorter or longer time periods. A good example of the ways in which changing nutrient intake may or may not be reflected in blood and tissue nutrient status comes from vitamin A physiology. Preformed vitamin A intake is markedly variable with post-prandial increases in retinyl esters dependent on chylomicron transport. However, with hepatic storage, since there is a serum homeostatic mechanism in retinol-binding protein (RBP),⁴⁰ fasting vitamin A concentrations are rela-

tively constant. In contrast, provitamin A carotenoids are transported by lipoproteins, along with non-provitamin A carotenoids such as lycopene.

There are also seasonal variations in dietary intake and those that take place in relation to intercurrent illness or treatments for these illnesses. More than is the case with single drug studies, food-derived nutrients or other components present demanding design requirements. At the very least, clinical trials in food and nutrition will always require documentations or standardization of the background diet. Ultimately, designers may wish to take into account the dynamics of human eating by undertaking studies in non-steady state conditions. Rapid and repeated measurements and advanced data processing may allow this. For example, continuous measurement of energy expenditure may allow an understanding of its determinants in non-steady state conditions.

Nutritional contributors to metabolic pathways: The nutritional mechanisms for health and disease

Much of the focus of the study of food and metabolic pathways and, through them, health outcomes has been on intermediary metabolism, the role of vitamins, and the related focus on what we now regard as classical vitamin deficiency syndromes.⁴¹ The relatively later appreciation of essential trace elements greatly expanded the knowledge of nutritionally dependent metabolic pathways, notably those dependent on the many metallo-enzymes.

Inborn errors of metabolism have greatly improved our understanding of nutritional influences on metabolism (e.g. phenylketonuria). The food factors, which were found to inhibit enzymes or induce them, further developed this area.

The realization that food and beverage intakes could be important in carcinogenesis paved the way for an analysis of diet-genetic interactions which could alter metabolic events.^{42,43}

The most recent shift in thinking has been the recognition that food intake and nutritional status can modulate gene expression.^{13,44} Each of these modes of operation of diet on metabolism may be addressed in a clinical nutrition trial. Understanding them will advance the understanding of the nutritional basis of health and disease. However, it must also be acknowledged that the nutritionally related ways in which health is achieved and diseases develop are more complex, involving socio-anthropological and behavioural pathways (e.g. social anchorage, food beliefs and behaviour knowledge).^{45,46}

Advances in food technology

The development of nutrition science and food technologies has brought new insights to the knowledge of food for use in health and disease. This is most obvious in the conceptualization of functional foods; that is, food for specified health uses. Functional foods may be categorized into medical and non-medical. They are sometimes called designer foods, if they are newly created, although some are traditional foods or derived from traditional food technologies. It could be argued that the way in which breakfast cereals are being transmuted to deal with perceived micronutrient problems or dietary fibre deficiency problems make them 'functional'. Tofu or soy beancurd, if used as a source of phytoestrogens,

may be an example of a traditional food requiring functional food categorization for this application.

The following three criteria may be used to define functional foods:

1. Foods which are positioned in the diet to contribute to the maintenance and improvement of health or to the management of disease. Given that functional foods are intended for regular, if not daily, consumption, their development has implications for the nature of food habits and food practices and therefore health outcomes.
2. Edible or potable items made from common food ingredients and used as foods, rather than in the common forms of medication, such as tablets or capsules; the grey area is that of liquids and powders with potential specific health uses.
3. Items that can be consumed by individuals in the course of usual eating episodes.

Another advance in nutritional science has been the development of 'nutritionally complete' (as far as we know) formula feeds, such as Modifast[®], Ensure[®], Sustagen[®], and other diets which are 'elemental' (i.e. broken down to the basic building blocks of macronutrients; for example, amino acids or peptides instead of protein). Formula feeds are designed for use by individuals suffering from diseases which make the use of ordinary solid foods difficult or where ordinary food needs to be replaced for therapeutic reasons. The products can, however, be used as supplementary foods although they are formulated to sustain life in their own right.

Functional foods may be consumed by healthy people or individuals with borderline health. They aim either to prevent the deterioration of health or maintain health in those who have definable health problems. Formula feeds are used where disease prevents ordinary food from being used or where ordinary food must be avoided for extended periods of time; thus, a requirement of such products is that they are nutritionally complete. The foods may also be used to assist recovery from acute illness or surgery (e.g. by stimulating immune function or wound healing) and to prevent the development of complications (e.g. those of diabetes).

Mostly, functional foods will be consumed by healthy or borderline-healthy individuals with the aim of maintaining health or preventing the deterioration of health, respectively. Alternatively, formula feeds may be consumed by individuals suffering from certain diseases with the aim of assisting recovery and preventing the development of complications of disease.

Objectives and end-points for clinical trials in relation to the use of food, nutrients or other food components

Objectives

Exploring the nutritional basis of health and disease.

Socio-anthropological and behavioural objectives One of the most crucial issues in food and health is what determines, and how change can be wrought in, food selection. To date, this enquiry is often left to market researchers but clinical trials in this area will become more important as certainty about attribution is required, along with the extent of unintended consequences. For example, researchers need to explore what the substitution of low for high sodium (or sweetness, or fat, or spiciness, or dietary fibre) food or cooking practices does to overall food selection, and why.

Food or meals with particular physiological effects A particular food or a meal can have physiological effects greater than the sum of their components or parts and these are worthy of study. For example, milk or yoghurt may yield various biologically active properties (angiotensin-converting enzyme inhibitors)⁴⁷ or hormone-like compounds (e.g. the caseomorphins) in a way that isolated protein may not.⁴⁸

Breakfast has been much studied as a meal which can induce changes in cognitive or motor function.⁴⁹ More work is required on snacking and other occasions of eating, together with overall patterns.

Nutrient effects These may be located at the assimilation, lymphatic or blood transport, tissue, enzymic or molecular level, as discussed earlier. Each location could be the focus of a clinical trial.

Non-nutrient components of food As knowledge of the myriad components of food increases, along with knowledge of their biological effects on the human species, clinical trials aimed at discovering their effects on human biological mechanisms will be carried out. For example, trials could be conducted to determine whether phytoestrogens operate on a hierarchy of receptors in conjunction with endogenous oestrogens; whether they operate in bone in the same way in men and women; and whether they alter prostatic function.²⁶

Enhancing health status. There are expectations that food will not only prevent us from dying of hunger, developing deficiency diseases and, when eaten correctly, allow us to avoid diseases of excess, but that it will somehow allow us to feel better on a day-by-day basis. Few would doubt that it does these things (as judged even by the assuagement of hunger), but the scientific basis for this is weak and precludes

the development of food products which might further enhance health.

More specific end-points might therefore be helpful, such as sense of well-being, mood and sense of humour, which usually require scaling techniques or composite scores.⁵⁰⁻⁵² These techniques may be sensitive indicators of food toxicity as well as food benefit.⁵³

Decreasing risk or preventing disease. This requires the definition of risk factors for each nutritionally related disease. Some of these diseases may as yet be obscure. The food hormone-human physiology paradigm is an example of how new possibilities for nutritional pathways to disease can be opened up for investigation. The steps in enquiry, then, are to trial food and food components which may alter risk factors, followed by the trialling of disease process, and then by the trialling of disease outcomes.

Controlling a disease or preventing its complications. Disease process (as in arterial wall changes, cognitive impairment or factors underlying these events), disease outcome (e.g. ischaemic heart disease or dementia) or disease complications (e.g. congestive heart failure or incontinence) are each amenable to clinical trials with a nutritional intervention but time-frames to development will affect cost and feasibility, as will sample size requirements. At the end of the day, it will sometimes be necessary to make the best fit of different lines of evidence.

Curing a disease. A cure is much more likely with a rapid-onset food component deficiency (e.g. iron deficiency diseases) or tissue accumulation (e.g. of fat in obesity or cholesterol in the arterial wall), unless there is irreparable damage, than with slow-onset nutritionally related NCD (e.g. osteoporosis).

Table 1. Some adverse effects and toxicological issues for clinical trials in nutrition

System	Potential adverse effect	Example of food factors
Cardiovascular system	Cardiac output Atherosclerosis	Alcohols as cardiac depressants Various food factors which contribute to atherogenesis
Central nervous system	Behavioural Cognitive function	Biogenic amines, salicylates, MSG ⁵⁶ Zinc ¹⁸ , ginkgo alkaloids, oxidants, (e.g. PUFA), antioxidants (e.g. glutathione) ⁹³
	Headache Visual	Variable caffeine intake Oxidants, PUFA
Gastrointestinal tract	Nausea, vomiting, gut motility Digestion, absorption Gut microflora, gut immunity	Akinetic agents, food physico-chemistry, trypsin inhibitors Probiotics/antibiotics, glutamine deficiency
Genetic	Mutagenesis Oncogenesis	Aflatoxins Food viruses
Growth	Linear growth velocity	Growth factors and antigrowth factors
Hematologic	Erythropoiesis, myelopoiesis, megakaryopoiesis	Various hematinic deficiencies
Immune system	Natural Humoral Cellular	Folate, glutamine deficiency Protein deficiency Various micronutrient deficiencies, glutathione deficiency ⁵⁷ , flavonoid deficiency ⁵⁸
Musculoskeletal system	Muscle mass and function Bone density Joint architecture	Protein deficiency, respiratory chain inhibitors Osteoclast activators Excessive nucleic acid intakes
Respiratory system	Bronchial reactivity Diffusing capacity	Salicylates, MSG, biogenic amines, and other sensitizers Moulds, aflatoxins

PUFA, polyunsaturated fatty acids; MSG, monosodium glutamate

Arrest of the disease process is more likely than is a cure. In both situations, factors which may lead to nutritional relapses need to be understood and, ideally, taken into account in longer term trials.⁵⁴

Documenting and defining adverse effects. The question of appropriate toxicology is an important one in clinical trials of a nutritional kind (Table 1). In many ways, adverse effects should be sought as for drug trials. The reasons why assumptions should not be made about safety on the grounds that ingredients have long been in use are those of dose, vehicle of usage, duration and timing of exposure, food cultural guidance and constraints, and the health status of exposed individuals. Predicted total intakes, on the basis of prevailing food habits, become particularly important in relation to acceptable daily limits.⁵⁵

Much contemporary food toxicology (or food additives toxicology) is restricted to questions of mutagenicity or adverse organ effects (e.g. liver, kidney, skin) in experimental animal studies. Questions of change in human intestinal microflora, cognitive function, cardiorespiratory performance, muscle function, immune function and the like are rarely addressed. Again, whatever the clinical trials show, long-term monitoring and surveillance needs to be possible and available in places where new products are introduced.

Considering the nutritional consequences of pharmacotherapeutic interventions. Inasmuch as pharmacotherapy may alter food intake, change body composition or condition essential nutrient requirements, nutritional end-points are a reasonable part of clinical trials in general.

End-points

Each objective presents a range of possible end-points for clinical trials, embracing the following categories of variables: food intake, body composition, functional status (e.g. strength and work performance, immune function, cognitive function), disease risk factors (e.g. diabetes, cardiovascular disease, osteoporosis) and disease incidence (e.g. cancer). Table 2 lists various end-points for clinical trials in nutrition.

Food and nutrition versus drug trials

Similarities and dissimilarities There are similarities and dissimilarities between food or nutrition and drug trials. Both food and drug trials may provide evidence of ways in which health may be improved and maintained. They may also address similar morbidity and mortality. However, there are several dissimilarities between food or nutrition and drug trials which are listed in Table 3. Good study design and narrow entry criteria for subjects being studied, with rigorous conduct of the study, will help to reduce the caveats in food and nutrition trials. Particular note should be taken of the following: (i) the fact that food is generally recognized as safe, although this will change (e.g. progress towards phase 1, 2 and 3 trials); (ii) the need to evaluate the side-effects and toxicology of newer foods and food technologies; (iii) the trend with drug trials that, while a single outcome is usually of interest, this is changing towards quality of life measures and total morbidity and mortality: these measures can be an invaluable part of nutrition trials; (iv) the likely higher adherence with drugs and, therefore, the extra insight, effort and design required with food studies; (v) bias in application of findings through advocacy by food or pharmaceutical industries; and (vi) the expectation that food intervention will be

safer than drugs, although novel food products may be quite uncharacteristic of the historic food supply and, therefore, of relatively unknown risk.

Risk-benefit considerations Given the above analysis, risk-benefit considerations may be more subtle and longer term with food than with drugs but no less in need of evaluation.

Methodological issues

A clinical trial is an epidemiological study design. It differs from cohort and observational studies. A clinical trial allows the investigator to allocate treatment at random and has the potential to produce high quality results that resemble the controlled experiment.⁵⁹ Clinical trials can be categorized as being therapeutic or preventive. Nutrition support is a special form of therapeutic trial, while community nutrition intervention is a trial aimed at disease prevention (primary prevention). Nutrition support almost always focuses on individuals. Primary prevention trials in nutrition, on the other hand, assess end-points at the individual and population levels.

Nutrition support and community nutrition intervention trials, while each having a different focus in their objectives, require similar consideration in the design and conduct of the trial, sample size calculation, data base management, and statistical analysis. Clinical trials in nutrition require special consideration. Such consideration includes that of methodological issues related to the maintenance and assessment of background diet, and measurement of errors associated with nutrition assessment (not necessarily contemplated when they are not laboratory-based, as with anthropometry).

Design and conduct of clinical trials

There are at least three issues in the design and conduct of clinical trials: (i) identification and recruitment of a study population; (ii) delivery of the intervention and assessment of compliance; and (iii) ascertainment of quality end-points.⁶⁰

Identification and recruitment of a study population. Clinical trials begin with design issues in population selection. Within the population hierarchy, a study population is nested under the reference population to whom results of the intervention trial are generalizable. Members of the reference population who meet the entry criteria of a trial are called the experimental population. In a nutrition trial, an experimental population eliminates individuals who can potentially bias intervention outcomes or contribute to a decreased power of the statistical test. At the same time, this may limit the ultimate generalizability of the findings. A long-term clinical trial relies on complete and accurate follow-up information. Thus, an experimental population selection needs to take into account follow-up rate. Once the experimental population is defined, members can then be invited to take part in the study. A study population consists of individuals who are eligible and willing to participate in the trial. In a nutrition trial, members of the study population would be allocated to either a dietary intervention group(s) or comparison group(s).

The ultimate goal of a nutrition trial is to establish the effect of the intervention. For the trial outcome to be sufficiently explained by the intervention, factors which determine the experimental population, the characteristics of the study population and, finally, the intervention allocation also

Table 2. End-points for clinical trials in nutrition

Intervention	Category	End-points Variable	Significance and cautions
Socio-anthropological and food beliefs: social network, economic factors, organizational factors, food supply Nutritional education or behaviour therapy Food commodity comparisons (e.g. meat versus fish, rice versus wheat)	Food intake	Food practices Food indices (food variety, nutrient-dense food, energy-dense food, food acculturation scores) Alcohol intake Nutrient indices Other food component indices	When changed in favorable direction, improvement in well-being, and/or health status may follow, as judged from other studies Evaluate consequential change in background diet, food cultural intactness (eg Swedish study of social factors on nutrient intakes from dairy products)
Food/nutrient supplementation or restriction Food commodity comparisons Food analogue (e.g. functional food or formula feeds) Physical activity Pharmacological agent	Body composition	Fat free mass Fat mass Fat distribution Bone density Water Organ size	Indicative of protein and related whole body nutritional status Reflects energy stores and metabolic phenomena of importance in chronic non-communicable diseases Bone strength, fracture proneness, nutrient stores (e.g. zinc) Integrity of body water regulatory phenomenon Relates to specific organ function (e.g. cardiac, immune system (spleen)) Consider extent to which weight change comprises a body compartment and its function. Assessment of nutritional reserve and margin for error in tissue stores
Food/nutrient supplementation or restriction Food commodity comparisons Food analogue (e.g. functional food or formula feeds) Physical activity Pharmacological agent	Functional status	Muscle strength Work performance Haematological status Vision (e.g. dark adaptation) Cognitive function Immune function	Indices of performance, well-being, and proneness to disease addressed. Function may fluctuate and not be related to intervention; thus, study design needs to be of sufficient duration to take this into account Degree of unintended functional compromise in one domain when another is advantaged must be considered
Food/nutrient supplementation or restriction Food commodity comparisons Food analogue (e.g. functional food or formula feeds) Physical activity Pharmacological agent	Risk factors for disease	<i>Cardiovascular:</i> abdominal fatness, blood pressure, lipoproteins, platelet function, glycaemic status, physical fitness <i>Diabetes:</i> abdominal fatness, physical inactivity <i>Osteoporosis:</i> body mass index, calcium intake, sodium intake, caffeine intake, phytoestrogen intake, physical activity, cigarette smoking <i>Neoplastic disease:</i> body fatness, fat intake, plant food intake, preserved food intake, alcohol intake, physical activity, cigarette smoking	Greater opportunities for prevention of disease once risk defined and corrected Correction of risk factor may have other effects which are adverse
Food/nutrient supplementation or restriction Food commodity comparisons Food analogue (e.g. functional food or formula feeds) Physical activity Pharmacological agent	Mortality	Disease-specific mortality Total mortality	Encourage disease avoidance through nutritional and other means and strategies which will have favourable effects on different kinds of premature death It may be difficult or costly in time to detect or prevent chronic disease-related mortality

Table 3. Likely dissimilarities between food/nutrition and drug trials

	Food and nutrition trial	Drug trial
Form	Complex	Simple
Compliance	Low	High
Biochemical interaction		
Within components	High	Low
With other components	High	Low
Metabolism	Complex	Simple
Bioavailability	Low	High
Measurable outcomes	Low yield	High yield
Dose response	Shallow slope	Steep slope
Side effects	Low	High
Investigator workload	High	Low
Time for study	Long	Short

need to be taken into account. Problems associated with experimental population selection can be reduced by clearly defining the health issues or research questions, the priority population or high-risk group, the end-points or outcome measures, and the goals and targets. Investigators of a strictly defined trial may find that the size of the experimental population is too small to allow an adequate number of study subjects. This may be overcome by a multicentre approach. As in pharmacological trials, investigators of nutrition trials often find it difficult to obtain adequate information about the non-respondents. Whether or not characteristics of the study population match those of the non-respondents is an essential enquiry for results of an intervention to be generalizable to the experimental, and hence, reference population.⁶¹ This may be overcome by collecting baseline or outcome data from all eligible individuals of the experimental population.⁶² In order to eliminate bias in intervention allocation, randomization techniques are used.^{63,64} There is a range of randomization techniques, specifically designed to answer defined research questions.⁶⁵

Delivery of the intervention and assessment of compliance. Following randomization, trial investigators will intervene and monitor compliance. A nutrition intervention may be delivered by single or combined nutrient supplements,^{66–69} nutrition education or counselling,^{70–73} or food-based supplements.⁷⁴ The combination of all three intervention deliveries was adopted for the Australian Polyp Preventive Project, in which β -carotene (single nutrient) and a wheat bran (food-based) supplement, as well as fat reduction (nutrition counselling) were employed.²¹ The use of various interventions needs to take into account study settings (therapeutic vs preventive), appropriate randomization techniques and, most importantly, the underlying research question and study objectives.

A more challenging aspect of a nutrition trial is the assessment of compliance. This is particularly relevant to intervention by way of an education program or counselling where the objective is to change a specific aspect of nutrient intake. Nutrition intervention means that study subjects take part in a prescribed regimen that aims to alter their nutritional status and, subsequently, health outcomes. The quality of end-points or outcomes depends on the degree to which nutrition intervention is maintained (compliance). Two factors known

to affect compliance are the length of the trial period and the complexity of the study protocol (randomization and intervention delivery). Various strategies have been developed to enhance compliance.⁷⁵ In the Multiple Risk Factor Intervention Trial (MRFIT), it was found that nutrition intervention contributed to outcomes through both the continuing efforts of the nutrition counsellors and the level of dietary adherence.⁷⁶

Ascertainment of quality end-points. Quality end-points in nutrition trials address efforts to achieve uniform ascertainment of outcomes from both intervention and comparison groups, and complete follow-up of study subjects over the trial period. In order to eliminate outcome observation bias, 'blinding' techniques (single or double) have been developed for drug trials. In nutrition trials where nutrition education or counselling may affect changes in other lifestyle factors, the use of single-blind or unblinded design is necessary. This raises several other issues which may also affect the quality of end-points. This includes possible unwillingness to stay in the prescribed nutrition regimen, over- or under-reporting the intervention to which the subject is prescribed, or unintended changes in background diet in intervention or comparison groups.

The completeness of follow-up of study subjects depends largely on the length of trial. Nutritional support (or therapeutic) trials are usually carried out in hospital and require short follow-up periods. In this setting, follow-up of all study subjects is easy for the entire trial period. A major cause of loss of follow-up is death. However, primary prevention trials often involve community groups or large cohorts, members of which are usually apparently healthy and not nutritionally depleted. These trials require many years of follow-up to observe study outcomes, usually the occurrence of disease or death. People are population-dynamic; they move, change jobs or names, and lose touch with the trial organization. As the length of trial period increases, the extent of complete follow-up of all study subjects decreases. The loss of follow-up can bias the effects of intervention on outcomes. For trials where mortality is an end-point, a national or state death register can be used to obtain the vital status of all study subjects.⁷⁷ It is now also usual trial practice to require subjects to provide the name, address and telephone number of a close relative or friend who may be contacted, in case of difficulty in follow-up.

Sample size

Sample size calculation in clinical trials relates to the ability to detect differences between intervention and comparison groups that are of clinical significance.⁶⁴ Sample size in clinical trials is thus an issue of statistical power. Generally, the calculation is on the basis of comparison of a single mean with a standard or a comparison of two means.⁷⁸ However, where the confidence in a trend or relationship is sought, the statistic of the intercept or slope of the line is what must be considered, with the number of points on the line improving the power. Intercepts or slopes may be compared.

If the underlying differences between the intervention and comparison groups are affected by compliance and quality of end-points, the sample size will need to be larger.

Accumulation of adequate end-points. A high-risk population approach ensures accumulation of a sufficient number

of end-points. Nutrition support trials enrol almost exclusively high-risk individuals and require relatively small numbers of study subjects to achieve clinical significance between experimental groups. Using as few as 34 patients with alcoholic hepatitis, Simon and Galambos were able to demonstrate that peripheral parenteral nutrition compared with standard therapy rapidly improved liver function and morbidity.⁷⁹ Large scale prevention trials also rely on a high-risk population approach to minimize the spread (variance) of end-points and, hence, improve statistical power. This is equivalent to the use of entry criteria to establish an experimental population. A common high-risk approach is to set an age limit. A suitable duration of follow-up can influence quality of end-points as well as accumulation of adequate end-points. More importantly, an inadequate trial period can decrease the power of statistical tests.

Effect of compliance. Poor compliance can result in similarity between the intervention and comparison groups, and decrease the ability to detect the true difference. Additionally, poor compliance can introduce bias that results in increased variance in intervention or comparison groups and, hence, the decreased power of tests.

Food and nutrient database management

Database management and statistical analyses are important considerations in all clinical or intervention trials. In nutrition trials, particularly those involving education programs or counselling, food and nutrient intake data management and analyses are generally necessary. Food intake data are first collected and then converted into nutrients. There is nutrient conversion software such as Nutritionist-III (N-Squared Computing, Salem, OR, USA) and Diet/1 (Xyris Software (Australia), Queensland, Australia) that allows the direct conversion of food to nutrient intakes. They depend on various food comparison tables which need to be defined. The ability to incorporate food and nutrient with non-nutrient data in the statistical analyses is becoming of increasing interest. For investigators who do not have access to nutrient conversion software, database management software can be used. Food intake data are stored, preferably in a computer, in the form in which they are collected. This allows each food or beverage to be averaged as daily intake per gram, and grouped for later use. The preservation of intake data in relation to time of day, day of week, or season is increasingly required.

Where more than one source of food composition tables is required, it is necessary to cross-check nutrients and measurement units. A new food composition database may be generated if relevant to the study population but will require description and definition in any report.

Background diet

A special feature of nutrition trials is the background diet, or non-intervention dietary intake. Community intervention (primary prevention) trials where the dietary goal is to reduce or increase specific nutrients can result in concomitant changes in background diet. In the MRFIT, the dietary goals were to progressively reduce fat intake as energy by 10% (from 35 to 25%), saturated fat as energy by 3% (from 8 to 5%), and dietary cholesterol by 150 mg per day (from 250 to 100 mg/day), with the energy adjusted to achieve 1.15 times the ideal body weight.⁷⁰ In order to achieve these dietary

goals, recommended food consumption patterns were designed to take into account existing food patterns and how food permeates daily living. In this trial, the intervention group underwent minimal changes at the beginning of the trial in their usual eating pattern, and then progressively moved to the study dietary goals. The ability to control background diet (and reference diet) in accordance with the nutrition intervention goals can provide participants with an incentive for dietary adherence, and allow the investigators to assess more accurately the effects of intervention.

Nutrition assessment

Measurement errors inherent in nutrition assessment methods, particularly dietary assessment, raise important methodological issues for all such nutrition studies, including nutrition intervention trials. The problem with diet is the lack of gold standard reference methodology. Validation is provided in part by a consideration of how sensible the energy intake in relation to BMR, by biochemical checks such as urinary nitrogen excretion, protein intake, and 'fingerprinting of plasma phytochemicals in relation to intake, along with prediction of outcome'.²²

Anthropometry, laboratory (e.g. body composition, biochemical tests and functional tests) or clinical methods can be used to assess nutritional status that cannot be otherwise adequately assessed by dietary means.

Limitations of food or nutrition trials

Age dependency

The importance of early life nutrition on later life health is increasingly understood.⁸⁰⁻⁸² Ideally, clinical trials for the aged would begin early in life, but this is not practical. The next best strategy is for trials to be undertaken in age segments and then the findings pooled across the life span in much the same way as is done for life expectancy tables at birth. The limitation is that the deductions may not always be valid.

Major community-based intervention studies should now seek to reserve genetic and biological material so that subsequent generations of investigators might take advantage of earlier research programs.

The use of single food or nutrients in trials and their interaction with other nutrients

Univariate, reductionist scientific methodology usually prevails in clinical trials but the findings from such trials have limited applicability. Design which acknowledges the multivariate nature of food, food habits and food effects will, in general, be superior. However, even here, the cooperativity, synergistic, additive and confounding effects of various food components will need to be acknowledged.

Appropriateness of extrapolation of results from a trial setting to the broader population in various clinical situations

Representativeness. There is a tendency for clinical trials to be carried out in non-representative populations and, while they are valid in regard to that particular population, they may not be valid for a representative population or another group of individuals. Increasingly, it could be argued that

clinical trials ought to be carried out in samples representative of the population for which the findings are intended.

Adherence and compliance. Nutritional intervention requires various periods of time before beneficial effects become evident. Longer studies affect patient compliance. In addition, the form of nutritional intervention, whether food (i.e. functional food) or formula feeds (i.e. elemental diets), may not be sufficiently palatable or interesting to gain adherence to the regimen. Again, extrapolation of results to a less supervised free-living setting may be difficult.

Confounding factors. Lifestyle, food habits and health status are inseparable. The ability of health-care providers to understand the food culture of patients and wider society is crucial in order to avoid misapplication of advice based on a clinical trial. For example, fish, which is rich in ω -3 fatty acids, consumed two times per week is likely to prove beneficial as far as certain cardiovascular risk factors are concerned.⁸³⁻⁸⁷ However, the cooking habits practised by certain cultures (e.g. the Chinese tendency to add soy sauce to fish dishes) might negate the putative beneficial effects by increasing sodium intake.⁸⁸

Limits to extrapolation from cross-sectional studies. The clinical trial helps to ensure that deductions from cross-sectional studies have cause and effect validity. Many cross-sectional studies on food, nutrition and health are available; most of them are population-based studies which provide an operational case for a possibly useful intervention. These cross-sectional situations allow it to be seen that different nutritional pathogenesis may operate for the same disease outcome in different ethnic groups (e.g. selenium deficiency cardiomyopathy in China,⁸⁹ or cobalt excess cardiomyopathy in Europe).^{90,91}

Inefficiencies in intervention investment and the nature of meaningful outcome measures. As well as health costs and benefits, the economic and environmental costs and benefits of interventions need to be taken into account. Increasingly, the considerations are economic but rarely ecological.

Intermediate changes versus ultimate morbidity and mortality outcomes. It is often of particular investigatory value to seize upon intermediates in the pathway between food and disease or death as achievable outcome measures. However, like the requirement with age-related outcomes, the various steps in the nutrition-health pathway require amalgamation and even this deductive and synthetic logical process does not always fulfil expectations.

Ethical issues

There are a number of unique ethical issues relating to nutrition, as follows: (i) the issue of prevention; (ii) the issue of the individual's right to be fed, which relates to the long-term poorly identifiable effects of change in diet and the unintended consequences on background diet; (iii) the issue of disruption of food-cultural tradition and its associated belief systems; and (iv) issues which impact on the overall security of the food supply and its sustainability.^{25,92}

In summary, the design and conduct of a clinical trials in nutrition are more demanding than the corresponding drug trials, although the need for such trials will rapidly grow.

References

1. Wahlqvist ML. Food as therapy. In: McLean AJ, Wahlqvist ML, eds. Current problems in nutrition pharmacology and toxicology. London: John Libbey and Company Ltd, 1988; 1-15.
2. Hetzel BS. The elimination of iodine deficiency disorders as a public health problem by the year 2000. In: Wahlqvist ML, Truswell AS, Smith R, Nestel P, eds. Nutrition in a sustainable environment. Proceedings of the XV International Congress of Nutrition: IUNS Adelaide. London: Smith-Gordon and Company Ltd, 1994; 273-280.
3. Willett W. Nutritional epidemiology. In: MacMahon B, ed. Monographs in epidemiology and biostatistics. New York: Oxford University Press, 1990.
4. Rand WM, Uauy R, Scrimshaw NS, eds. Protein energy requirement studies in developing countries: results of international studies. Tokyo: United Nation University Press, 1984.
5. Boivin MJ, Giordani B. Improvements in cognitive performance for school children in Zaire, Africa, following an iron supplement and treatment for intestinal parasites. *J Pediatr Psychol* 1993; 18: 249-264.
6. Basta SS, Soekirman Karyadi D, Scrimshaw NS. Iron deficiency anemia and the productivity of adult males in Indonesia. *Am J Clin Nutr* 1979; 32: 916-925.
7. Pollitt E. Iron deficiency and cognitive function. *Annu Rev Nutr* 1993; 13: 521-537.
8. International Vitamin A Consultative Group (IVACG). Guidelines for the eradication of vitamin A deficiency and xerophthalmia. Port-au-Prince, Haiti: IVACG, 1976.
9. Burke TIA, Rolmer JV, Henry CJ, eds. Regulation risk: the service and politics of risk. Washington DC: International Life Science Institute, 1993.
10. Expert Panel on Folate Fortification of the National Health and Medical Research Council. Report to the 117th Session of council. Australian Government Publishing Service, Sydney, New South Wales, 1994.
11. Rush D. Periconceptual folate and neural tube defect. *Am J Clin Nutr* 1994; 59 (Suppl.): 511S-516S.
12. Truswell AS. Evolution of dietary recommendations, goals and guidelines. *Am J Clin Nutr* 1987; 45: 1060-1072.
13. Simopolous AS, Herbert V, Jacobson B, eds. Genetic nutrition: designing a diet based on your family medical history. New York: MacMillan Publishing Company, 1993.
14. Dwyer T, Hetzel BS. A comparison of trends of coronary heart disease mortality in Australia, USA and England and Wales with reference to three major risk factors - hypertension, cigarette smoking and diet. *Int J Epidemiol* 1980; 9: 65-71.
15. Wahlqvist ML. International trends in cardiovascular diseases in relation to dietary fat intake: inter-population studies. In: Proceedings of the XIII International Congress of Nutrition, Brighton. London: John Libbey and Company Ltd, 1986; 539-543.
16. Blankenhorn DH. Two new diet-heart studies. *N Engl J Med* 1985; 312: 851-853.
17. Hodgson J, Wahlqvist ML, Balazs ND, Boxall J. Can linolenic acid contribute to coronary artery disease? *Am J Clin Nutr* 1993; 58: 228-234.
18. Cassidy A, Bingham SA, Cummings JH. Starch intake and colorectal cancer risk: an international comparison. *Br J Cancer* 1994; 69: 937-942.
19. Greenberg ER, Baron JA, Tosteson TD, Freeman DH, Beck GJ, Bond JH, Colacchio TA, Coller JA, Frankl HD, Haile RW, Mandel JS, Nierenberg DW, Rothstein R, Snover DC, Stevens MM, Summers RW, van Stolk RU. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. *N Engl J Med* 1994; 331: 141-147.
20. McLennan R. Fat intake and cancer of the gastrointestinal tract and prostate. *Med Oncol Tumor Pharmacother* 1985; 2: 137-142.
21. McLennan R, Bain C, Macrae F, Gratten H, Battisutta D, Bokey EL, Chapuis P, Goulston K, Lambert J, Wahlqvist ML, Ward M. Design and implementation of the Australian Polyp Prevention Project. In: Rozen P, Reich CB, Winawer SJ, eds. Frontiers of gastrointestinal research. Basel: Karger, 1990; 60-73.
22. Bingham S. Food components and mechanisms of interest in cancer and diet in relation to their measurement. *Eur J Clin Nutr* 1993; 47 (Suppl.): S73-S77.

23. Negri E, La Vecchia C, D'Avanzo B, Franceschi S. Calcium, dairy products, and colorectal cancer. *Nutr Cancer* 1990; 13: 255–262.
24. Regester GO. Whey protein based functional foods. In: *Proceedings of International Workshop: Functional foods – the present and the future*. Canberra: National Food Authority, 1994; 39–46.
25. Solomons NW. The ethics of prevention. In: Wahlqvist ML, Vobecky JS, eds. *Medical practice of preventive nutrition*. London: Smith-Gordon and Company Ltd, 1994; 291–306.
26. Vines G. Cancer: is soya the solution? *New Scientist* 1994; July: 14–15.
27. Wilcox G, Wahlqvist ML, Burger HG, Medley G. Oestrogenic effects of plant foods in postmenopausal women. *BMJ* 1990; 301: 905–906.
28. Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. *Lancet* 1992; 340: 1124–1127.
29. Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, Pollwein P, Beyreuther K, Masters CL. A novel zinc (II) binding site modulates the function of the beta-A4 amyloid protein precursor of Alzheimer's disease. *J Biol Chem* 1993; 268: 16109–16112.
30. Czech C, Forstl H, Hentschel F, Monning U, Besthorn C, Geiger-Kabisch C, Sattel H, Masters C, Beyreuther K. Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change. *Eur Arch Psychiatry Clin Neurosci* 1994; 243: 291–292.
31. Masters CL, Beyreuther K. Alzheimer's disease: a clearer definition of the genetic components. *Med J Aust* 1994; 160: 243–244.
32. Perrin R, Briancon S, Jeandel C, Arthur Y, Minn A, Penin F, Siest G. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: a case-control study. *Gerontology* 1990; 36: 306–313.
33. Nishijo H, Ono T. Food memory: neuronal involvement in food recognition. *Asia Pacific J Clin Nutr* 1992; 1: 3–12.
34. Wahlqvist ML, Hsu-Hage BH-H, Kouris-Blazos A, Lukito W, IUNS Study Centre Investigators. Food habits in later life — a cross cultural study. In: Wahlqvist ML, Truswell AS, Smith R, Nestel P, eds. *Nutrition in a sustainable environment. Proceedings of the XV International Congress of Nutrition: IUNS Adelaide*. London: Smith-Gordon and Company Ltd, 1994; 345–53.
35. Wahlqvist ML, Davies L, Hsu-Hage BH-H, Kouris-Blazos A, Scrimshaw NS, Steen B, van Staveren W, eds. *Food habits in later life: cross cultural approaches*. Melbourne: Asia Pacific Journal Clinical Nutrition, 1995.
36. Beilin LJ, Armstrong BK, Margetts BM, Rouse IL, Vandongen R. Vegetarian diet and blood pressure. *Nephron* 1987; 47 (Suppl.): 37–41.
37. Beilin LJ, Armstrong BK, Margetts BM, Rouse IL, Vandongen R. Vegetarian diet and blood pressure levels: incidental or causal association? *Am J Clin Nutr* 1988; 48 (Suppl.): 806–810.
38. Jenkins DJ, Jenkins AL, Wolever TM, Vuksan V, Rao AV, Thompson LU, Josse RG. Low glycemic index: lente carbohydrates and physiological effects of altered food frequency. *Am J Clin Nutr* 1994; 59: 706S–9S.
39. Boulton TJC, Nichols J, Magarey A. Food patterns in youth and their effect on later life. In: Wahlqvist ML, King RWF, McNeil JJ, Sewell R, eds. *Food and health: issues and direction*. London: John Libbey and Company Ltd, 1987; 6–11.
40. Olson J. Vitamin A. In: Brown ML, ed. *Present knowledge in nutrition*, 6th edn. Washington DC: International Life Science Institute Nutrition Foundation, 1990; 96–107.
41. Linder MC, ed. *Nutritional biochemistry and metabolism with clinical applications*. New York: Elsevier, 1991.
42. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries with special reference in dietary practice. *Int J Cancer* 1975; 15: 617.
43. Wahlqvist ML. Nutritional factors in carcinogenesis. *Asia Pacific J Clin Nutr* 1993; 2: 141–148.
44. Rucker RB. Molecular biology and nutrition. In: Wahlqvist ML, Truswell AS, Smith R, Nestel P, eds. *Nutrition in a sustainable environment. Proceedings of the XV International Congress of Nutrition: IUNS Adelaide*. London: Smith-Gordon and Company Ltd, 1994; 405–413.
45. Hansson BS, Mattisson I, Steen B. Dietary intake and psychosocial factors in 68-year-old men: a population study. *Compr Gerontol* 1987; B1: 62–67.
46. Kouris A, Wahlqvist ML, Trichopoulos A, Polychronopoulos E. Use of combined methodologies in assessing food beliefs and habits of elderly Greeks in Greece. *Food Nutr Bull* 1991; 13: 139–144.
47. Shimizu M. Bioactive peptides from bovine milk proteins. *Proceedings of 24th International Dairy Congress 1994*. Auscript, Sydney, Australia.
48. Hansky J. Neuroendocrine factors in food. In: McLean AJ, Wahlqvist ML, eds. *Current problems in nutrition pharmacology and toxicology*. London: John Libbey and Company, 1988; 77–80.
49. Howden JA, Chong YH, Leung SF, Rabuco LB, Sakamoto M, Tchai BS, Tontisirin K, Wahlqvist ML, Winaro FG, Yap M. Breakfast practices in the Asian region. *Asia Pacific J Clin Nutr* 1993; 2: 77–84.
50. Lawton MP, Moss M, Fulcomer M, Kleban MH. A research and service oriented multilevel assessment instrument. *J Gerontol* 1982; 37: 91–99.
51. Schiffmann SS, Reynolds ML, Young FW, eds. *Introduction to multidimensional scaling: theory, methods and applications*. New York: Academic Press Inc., 1981.
52. Teri L, Truax P. Assessment of depression in dementia patients: association of caregiver mood with depression ratings. *Gerontologist* 1994; 34: 231–234.
53. Wolraich ML, Lindgren SD, Stumbo PJ, Stegink LD, Appelbaum MI, Kiritsy MC. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. *N Engl J Med* 1994; 330: 301–307.
54. Wahlqvist ML, Vobecky JS, eds. *Medical practice of preventive nutrition*. London: Smith-Gordon and Company Ltd, 1994.
55. Briggs DR. Food sensitivities. In: Wahlqvist ML, ed. *Food and nutrition in Australia*, 3rd edn. Melbourne: Thomas Nelson Australia, 1992; 457–65.
56. Loblay RH, Swain AR. Adverse food reactions. In: Wahlqvist ML, King RWF, McNeil JJ, Sewell R, eds. *Food and health: issues and direction*. London: John Libbey and Company Ltd, 1987; 39–42.
57. Furukawa T, Meydani SN, Blumberg JB. Reversal of age-associated decline in immune responsiveness by dietary glutathione supplementation in mice. *Mech Ageing Dev* 1987; 38: 107–117.
58. Middleton E Jr, Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. *Biochem Pharmacol* 1992; 43: 1167–1179.
59. Hennekens CH, Buring JE, eds. *Epidemiology in medicine*. Boston: Little Brown and Company, 1987.
60. Taylor PR, Dawsey S, Albanes D. Cancer prevention trials in China and Finland. *Ann Epidemiol* 1990; 1: 195–203.
61. Friedman LM, Furberg CD, DeMets DL, eds. *Fundamentals of clinical trials*, 2nd edn. Littleton, MA: PSG, 1985.
62. Coronary Artery Surgery Study (CASS). A randomized trial of coronary artery bypass surgery: comparability of entry characteristics and survival in randomized patients and non-randomized patients meeting randomization criteria. *J Am Coll Cardiol* 1984; 3: 114–128.
63. Wilhelmsen L, Ljungberg S, Wedel H, Werko L. A comparison between participants and non-participants in a primary prevention trial. *J Chron Dis* 1976; 29: 331–339.
64. Yusuf S, Collins R, Peto R. Why do we need large, simple randomized trials? *Stat Med* 1984; 3: 409–422.
65. Fleiss JL, ed. *The design and analysis of clinical experiments*, 2nd edn. New York: John Wiley and Sons, 1986.
66. Greenwald P. Experience from clinical trials in cancer prevention. *Ann Med* 1994; 26: 73–80.
67. Ignoffo RJ. Parenteral nutrition support in patients with cancer. *Pharmacotherapy* 1992; 12: 353–357.
68. Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW. Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. *Cancer Res* 1987; 47: 3309–3316.
69. Viall C, Porcelli K, Teran JC, Varma RN, Steffee WP. A double-blind clinical trial comparing the gastrointestinal side effects of two enteral feedings. *JPEN* 1990; 14: 265–269.

70. Gorder DD, Dolecek TA, Coleman GG, Tillotson JL, Brown HB, Lenz-Litzow K, Bartsch GE, Grandits G. Dietary intake in the Multiple Risk Factor Intervention Trial (MRFIT): nutrient and food group changes over 6 years. *J Am Diet Assoc* 1986; 86: 744–751.
71. Gritz ER, Bastani R. Cancer prevention — behavior changes: the short and the long of it. *Prev Med* 1993; 22: 676–688.
72. Simons-Morton DG, Mullen PD, Mains DA, Tabak ER, Green LW. Characteristics of controlled studies of patient education and counseling for preventive health behaviors. *Patient Educ Coun* 1992; 19: 175–204.
73. Stamler R, Stamler J, Grimm R, Gosch F, Dyer A, Berman R, Civinelli J, Elmer P, Fishman J, Van Heel N *et al*. Trial on control of hypertension by nutritional means: three-year results. *J Hypertens* 1984; 2 (Suppl.): S167–S170.
74. Ritenbaugh C. Dietary supplementation: the case for placebo-controlled trials. *Prev Med* 1993; 22: 667–675.
75. Buring JE, Hennekens CH. Sample size and compliance in randomized trials. In: Sestil MA, Dell JG, eds. *Chemoprevention clinical trials: problems and solutions*. NIH Publication No 85–2715. Hyattsville, MD: USDHHS, 1985.
76. Tillotson JI, Gorder DD, Duchene AG, Grambsch PV, Wenz J. Quality control in the Multiple Risk Factor Intervention Trial nutrition modality. *Controlled Clin Trials* 1986; 7 (Suppl.): 66S–90S.
77. Stampfer M, Willett WC, Speizer FE, Dysert DC, Lipnick R. Test of the National Death Index. *Am J Epidemiol* 1984; 119: 837–839.
78. Dawson-Saunders B, Trapp RG. *Basic and clinical biostatistics*, 2nd edn. Norwalk, CT: Appleton & Lange, 1994; 118–119.
79. Simon D, Galambos JT. A randomized controlled study of peripheral parenteral nutrition in moderate and severe alcoholic hepatitis. *J Hepatol* 1988; 7: 200–207.
80. Barker DJ. The intrauterine origins of cardiovascular disease. *Acta Paediatr* 1993; 82 (Suppl.): 93–99.
81. Barker DJ, Martyn CN, Osmond C, Hales CN, Fall CH. Growth in utero and serum cholesterol concentrations in adult life. *BMJ* 1993; 307: 1524–1527.
82. Osmond C, Barker DJ, Winter PD, Fall CH, Simmonds SJ. Early growth and death from cardiovascular disease in women. *BMJ* 1993; 307: 1519–1524.
83. Margetts BM, Beilin LJ, Armstrong BK, Rouse IL, Vandongen R, Croft KD, McMurchie EJ. Blood pressure and dietary polyunsaturated and saturated fats: a controlled trial. *Clin Sci* 1985; 69: 165–175.
84. Margetts BM, Beilin LJ, Armstrong BK, Vandongen R, Croft KD. Dietary fat intake and blood pressure: a double-blind controlled trial of changing polyunsaturated to saturated fat ratio. *J Hypertens* 1984; 2 (Suppl.): S201–S203.
85. Prescott SL, Jenner DA, Beilin LJ, Margetts BM, Vandongen R. Controlled study of the effects of dietary protein on blood pressure in normotensive humans. *Clin Exp Pharmacol Physiol* 1987; 14: 159–162.
86. Prescott SL, Jenner DA, Beilin LJ, Margetts BM, Vandongen R. A randomized controlled trial of the effect on blood pressure of dietary non-meat protein versus meat protein in normotensive omnivores. *Clin Sci* 1988; 74: 665–672.
87. Rouse IL, Beilin LJ, Mahoney DP, Margetts BM, Armstrong BK, Record SJ, Vandongen R, Barden A. Nutrient intake, blood pressure, serum and urinary prostaglandins and serum thromboxane-B₂ in a controlled trial with a lacto-ovo-vegetarian diet. *J Hypertens* 1986; 4: 241–250.
88. Hage BH-H. *Food habits and cardiovascular health status in adult Melbourne Chinese* [PhD thesis]. Monash University, Melbourne, 1992.
89. Levander OA. Scientific rationale for the 1989 recommended dietary allowance for selenium. *J Am Diet Assoc* 1989; 91: 1572–1576.
90. Horowitz SF, Fischbein A, Matza D, Rizzo JN, Stern A, Machac J, Solomon SJ. Evaluation of right and left ventricular function in hard metal workers. *Br J Ind Med* 1988; 45: 742–746.
91. Jarvis JQ, Hammond E, Meier R, Robinson C. Cobalt cardiomyopathy. A report of two cases from mineral assay laboratories and a review of the literature. *J Occup Med* 1992; 34: 620–626.
92. The Council for International Organizations of Medical Sciences (CIOMS). *International guidelines for ethical review of epidemiological studies*. Geneva: CIOMS, 1991.
93. Adams JD Jr, Klaidman LK, Odunze IN, Shen HC, Miller CA. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. *Mol Chem Neuropathol* 1991; 14: 213–226.